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Background: Recently, we have reported the induction of apoptosis by 2-amino-4-(3-nitrophenyl)-3-cyano-7-
(dimethylamino)-4H-chromene (3-NC) in HepG2, T47D and HCT116 cells with low nano molar IC50 values. In this study,
anti-proliferative effects of modified 4-aryle-4H-chromenes derivatives; 2-amino-4-(3-bromophenyl)-3-cyano-7-
(dimethylamino)-4H-chromene (3-BC), 2-amino-4-(3-trifluoromethylphenyl)-3-cyano-7-(dimethylamino)-4H-chromene
(3-TFC) and 2-amino-4-(4,5-methylenedioxyphenyl)-3-cyano-7-(dimethylamino)-4H-chromene (4, 5-MC) were
investigated in three human cancer cell lines. Compared to 3-NC none of the compounds displayed better
anti-proliferative effect, although 3-BC appeared somewhat similar. Therefore 3-NC was selected for further studies.
Methods and results: Treatment of HepG2, T47D and HCT116 cells with this compound induced apoptosis as
visualized by fluorescence microscopic study of Hoechst 33258 stained cells. Induction of apoptosis was quantified
by Annexin V/PI staining using flow cytometry.
Western blot analysis also revealed that 3-NC down-regulated the expression of anti-apoptotic protein Bcl2 and
up-regulated pro-apoptotic protein Bax, in all of the cell lines. Nonetheless, HepG2 cell line was the most responsive
to 3-NC as Bax and Bcl2 showed the most dramatic up and down regulation.
Conclusion: Our previous finding that 3-NC down regulates Inhibitor of Apoptosis Proteins (IAPs) and the present
observation that Bax is upregulated and Bcl2 is down regulated upon 3-NC treatment, this chromene derivative has
the potential to overcome chemotherapy resistance caused by up regulation of these proteins.
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Apoptosis is the prevalent form of program cell death
characterized by condensation of nuclear chromatin, loss
of plasma membrane phospholipid asymmetry, enzym-
atic cleavage of the DNA into oligonucleosomal frag-
ments, and segmentation of the cells into membrane-
bound apoptotic bodies [1, 2]. The Bcl2 family proteins
are key regulators of apoptosis cell death. These related
proteins share at least one of four homologous regions
termed Bcl homology (BH) domains (BH1 to BH4)
which control Bcl2 protein interactions. BH domains* Correspondence: majid.mahdavi@tabrizu.ac.ir
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unless otherwise stated.contribute at multiple levels to the function of these pro-
teins in cell death and survival. Currently about 25
members of this family have been identified that based
on functional studies and the conservation of BH do-
mains can be divided into three subgroups, pro-survival
Bcl2-like subgroup such as Bcl2, Bcl-xL, Mcl-1, Bcl-w
and A-1 which suppress cell death, and pro-apoptotic
Bax-like subgroup such as Bax, Bak, Bok and Bik which
promote cell death [3–5]. In living cell, Bcl2 and Bcl-xL
bind to the BH3 domains of pro-apoptotic family mem-
bers, sequestering them and thereby inhibiting their abil-
ity to promote cell death [6, 7]. The third subgroup
contains pro-apoptotic BH3-only proteins, such as Bad,
Bid, Bim, Noxa and Puma which can interact with either
anti-apoptotic proteins or pro-apoptosis members [3, 8].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Naseri et al. Cancer Cell International  (2015) 15:55 Page 2 of 9This subgroup can either inhibit the anti-apoptotic mol-
ecules or directly activate pro-apoptotic Bax or Bak to
induce apoptosis [9]. Although it is not fully understood
how Bcl2 family proteins regulate the apoptotic pathway,
it has been demonstrated biological functions of this
protein family is dependent on protein-protein interac-
tions [10–12].
It has been found that Bcl2 play an important role in
resistance of cancer cells to chemotherapy or radiation
therapy. Bcl2 can promote the expansion of neoplastic
cell by preventing normal cell turnover caused by
physiological cell death mechanisms [13, 14]. High ex-
pression of Bcl2 in various human cancers mediates the
resistance of cancers to a wide range of chemotherapeu-
tic drugs and γ-irradiation which act by inducing apop-
tosis in tumor cells. Therefore, the blocking of Bcl2 can
restore the apoptotic process in tumor cells. In this re-
gard, inhibitor molecules of Bcl2 may represent a new
class of therapeutic agents for cancer treatment [15].
Despite considerable progress in identifying the causes
of cancer and discovering new treatment strategies, sig-
nificant number of cancers remains resistant to chemo-
therapy. Consequently, numerous efforts are under way
to identify new compounds with anti-cancer activity the
4-aryl-4-H chromenes has been recently reported as a
new group of potent anti-cancer compounds. These
compounds bind to colchicine binding site in β tubulin
and destabilize microtubular assembly resulting in cell
cycle arrest at G2/M phase and apoptotic cell death
[16–18]. They were also active in the multidrug-resistant NH2
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Fig. 1 Chemical structure of the investigated 4-aryl-4H chromene derivativcancer cell lines and showed promising antitumor activ-
ity in several in vivo mouse tumor models with evidence
of antivascular activity [19, 20]. Further investigations
showed that substituent position on the phenyl ring are
more important, especially at the 3-position. Replace-
ment of the electron withdrawing groups at this position
of the phenyl ring was accompanied by a dramatic in-
crease in cytotoxic effects of these compounds. We thus
decided to position the strong electron withdrawing
groups of nitro (-NO2), Trifluoromethyl (-CF3) and
Bromo (-Br) on carbon 3 of the phenyl ring and also
Methylenedioxy (-MDO) on carbons four and five of the
ring (Fig. 1) to study their cytotoxic effects. In the previ-
ous study we reported concomitant activation of
caspase-nine and down-regulation of IAP proteins as a
mechanism of apoptotic death in HepG2, T47D and
HCT-116 cells upon exposure to 2-amino-4-(3-nitrophe-
nyl)-3-cyano-7-(dimethylamino)-4H-chromene (3-NC) from
4-aryl-4-H chromenes family [21]. In the present study we
demonstrate cytotoxic effects of the modified compounds
of 4-aryl-4-H chromenes family on these cancer cell lines
and show that 3-NC, in addition to down regulation of in-
hibitor of apoptosis proteins (IAPs), functions through
down regulation of Bcl2 and up regulation of Bax.
Materials and methods
Materials
The cell culture medium (RPMI 1640), fetal bovine serum
(FBS) and penicillin–streptomycin were purchased from
Gibco BRL (life technolologies, Paisley, Scotland). TheNH2
CN 
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Hoechst 33285 was purchased from Sigma Chemical
Company (Germany). MTT assay kit was purchased
from Roche (Germany). All antibodies, except β actin,
including anti-Bcl2 and anti-Bax were purchased from
Sigma (St Louis, MO, USA). β actin antibody was pur-
chased from Alexis Biochemicals (San Diego, CA).
Annexin-V-FITC kit was purchased from IQ product
(Groningen, The Netherlands). All cell lines were ob-
tained from Pasteur Institute of Iran (Tehran).
General procedure for the preparation of 4-aryl-4H-
chromene compounds
The 4-aryl-4H-chromene compounds were prepared ac-
cording to the previously described method [16, 22].
Briefly, condensation of 3-dimethylaminophenol, a
substituted benzaldehyde and malonitrile in ethanol in
the presence of piperidine yielded the 4-aryl-4H-chro-





7-(dimethylamino)-4H-chromene (3-TFC) and 2-amino-4-
(4,5-methylenedioxyphenyl)-3-cyano-7-(dimethylamino)-4H-
chromene (4, 5-MC) were established with IR, 1H
NMR, mass spectrometry and elemental analyses.
Cell culture and morphological evaluation of the
apoptotic cells
The HepG2, HCT116 and T47D cells were cultured in
RPMI-1640 medium supplemented with 10 % fetal bo-
vine serum (FBS), 2 mM L-glutamine, 50 IU/ml penicil-
lin and 50 μg/ml streptomycin. For morphological
studies, the cells were seeded in 12-well plates at 1 × 105
cells/well and treated with indicated concentrations of
the 3-BC, 3-NC, 3-TFC and 4, 5-MC for 72 h. Apoptosis
was determined morphologically by Hoechst 33258
staining using fluorescence microscopy. In brief, cells
were washed with cold phosphate-buffered saline (PBS)
and adjusted to a density of 1 × 105 cells per milliliter.
Hoechst 33258 solution (1 mg/ml ddH2O) was added to
the cell suspension at a final concentration of 100 μg/ml.
Cellular morphology was evaluated by Axoscope two
plus fluorescence microscopy (Zeiss, Germany).
In vitro cytotoxicity assay
The HepG2, HCT116 and T47D cells (1 × 105 cells/well)
were cultured in 12 well cell culture plates for 24 h prior
to treatment, then treated with indicated concentrations
of the 3-BC, 3-NC, 3-TFC and 4,5-MC in a CO2 incuba-
tor for 72 h. At the end of this period, 10 μl of MTT
(final concentration, 0.5 mg/ml) was added to each well
and the plates were incubated for 4 h at 37 °C.Afterwards, 100 μl of the solubilization solution (0.04 N
HCl in isopropanol) was added into each well and the ab-
sorbance values were determined at 570 nm using a micro-
plate reader (Elx 800 Microplate Reader, Bio-TEK) [23].
Annexin-V-FITC/PI double staining assays of the apoptotic
cells
Double staining with FITC-Annexin V and PI for flow
cytometry analyses was performed using phosphatidyle
serine detection kit including FITC-Annexin V (IQ
product, Netherland). The HepG2, HCT116 and T47D
cells were cultured for 24 h and incubated with indicated
concentrations (IC50 values) of 3-NC. The treated and/
or untreated cells harvested after 72 h and washed twice
with PBS, then resuspended in the binding buffer (cal-
cium buffer, 100 μl). FITC-Annexin V (10 μl) was added
to the cells followed by the addition of 10 μl PI. The
samples were then incubated for 10 min in the dark at
4 °C and then subjected to flow cytometer (Becton Dick-
inson FACS) evaluation.
Western blot analysis
HepG2, T47D and HCT116 cells were seeded and incu-
bated for 24 h and then treated with indicated dose
(IC50 values) of 3-NC. Following 48 h of treatment, the
cells were harvested and lysed using loading dye con-
taining, 1 % Triton X-100, 50 mM Tris-Cl (pH 6.8),
100 mM NaCl 1 % SDS, 10 % glycerol, β-
mercaptoethanol and Bromophenol blue. Protein con-
centration of each sample was determined using Lowry’s
method [24]. Equal quantities of protein (40-50 μg) were
loaded on 12 % SDS-polyacrylamide gel electrophoresis
(PAGE), and transferred to PVDF membranes. Transfer
of proteins was assessed by ponceau-red staining. Non-
specific binding membrane sites were blocked by incu-
bation in the blocking buffer [Tris-buffered saline (TBS)
buffer containing 0.1 % Tween 20 and 5 % non-fat dry
milk] for 1 h at room temperature. Subsequently, the
membranes were incubated with primary antibody (anti-
β actin, anti-Bcl2 and anti-Bax) at 4 °C overnight. There-
after, the membranes were washed in TBS, and incu-
bated with HRP conjugated secondary antibodies for 1 h
at room temperature. The proteins were detected using
enhanced chemiluminescence (ECL) detection system
(Thermo Scientific) [25]. Intensities of the bands were
quantified using the NIH ImageJ software (http://rsb.info.
nih.gov/ij/).
Statistical analysis
Data were derived from at least three independent ex-
periments and presented as means ± SD. Significant dif-
ferences were determined using the unpaired Student’s
t-test. Differences with p-values smaller than 0.05 were
considered significant.
Table 1 Cell viability in human cancer cells treated with various doses of the 4-aryl-4H-chromene derivatives for 72 h
R
Cell lines Concentration (nM) 3-BC 3-NCa 3-TFC Concentration (nM) 4, 5 MC
HepG2 0 100 100 100 0 100
50 61 ± 2.5 57 ± 3.1 91 ± 3.1 100 67 ± 2.1
55 53 ± 2.4 50 ± 4.2 89 ± 3.6 110 65 ± 1.6
60 50 ± 3.2 33 ± 2.1 87 ± 2.5 120 46 ± 2.5
65 43 ± 2.1 30 ± 3.6 82 ± 2.3 130 45 ± 2.7
70 42 ± 3.1 28 ± 3.3 76 ± 3.2 140 42 ± 3.6
75 40 ± 3.3 22 ± 1.2 65 ± 2.1 150 40 ± 2.5
80 37 ± 1.8 20 ± 2.1 53 ± 3.7 160 28 ± 3.3
T47D 0 100 100 100 0 100
50 80 ± 3.3 74 ± 1.5 86 ± 2.4 100 79 ± 3.5
55 60 ± 2.5 64 ± 2.3 75 ± 5.3 110 68 ± 4.1
60 53 ± 2.3 52 ± 3.5 72 ± 4.2 120 66 ± 4.2
65 51 ± 3.1 48 ± 4.6 64 ± 4.4 130 58 ± 2.4
70 48 ± 4.2 41 ± 2.6 61 ± 2.2 140 51 ± 3.2
75 45 ± 2.1 36 ± 2.5 50 ± 4.2 150 46 ± 4.5
80 42 ± 3.3 35 ± 1.3 44 ± 2.1 160 35 ± 3.2
HCT116 0 100 100 100 0 100
50 50 ± 3.5 50 ± 3.1 85 ± 2.5 100 70 ± 3.5
55 43 ± 2.4 42 ± 3.2 80 ± 3.6 110 67 ± 3.6
60 35 ± 3.2 37 ± 2.5 73 ± 4.5 120 65 ± 2.5
65 28 ± 2.1 30 ± 4.6 70 ± 3.3 130 62 ± 2.3
70 22 ± 4.1 22 ± 3.3 70 ± 1.2 140 60 ± 3.2
75 17 ± 3.1 15 ± 1.7 67 ± 3.4 150 54 ± 2.1
80 12 ± 3.3 12 ± 2.8 65 ± 3.0 160 50 ± 3.7
Cell viability was evaluated by MTT assay. Data were expressed as a percentage of control measured in the absence of the compounds. Each point represents the
mean ± SD of three independent experiments. (P < 0.05)
aData from Ref. [21]
Table 2 Inhibition of cell proliferation by 4-aryl-4H-chromenes
IC50a (nM)
Compound HepG2 T47D HCT116
3-BC 60 ± 3.0 65 ± 2.0 50 ± 3.0
3-NC 55 ± 2.0b 60 ± 3.0b 50 ± 2.0 b
3-TFC 80 ± 4.0 75 ± 4.0 75 ± 2.0
4, 5 MC 140 ± 3.0 160 ± 5.0 120 ± 4.0
aData are means of three or more experiments and are reported as means ±
standard error of the mean (SEM)
bData from Ref. [21]
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Anti-proliferative activity of investigated 4-aryl-4H-chromene
compounds
Growth inhibitory activity and IC50 values of 3-BC, 3-
NC, 3-TFC and 4, 5-MC compounds were evaluated
using MTT assay. HepG2, T47D and HCT116 cells, 1 ×
105 cells/ml were treated with various concentrations of
the chromene compounds for 72 h. Cell viability was ob-
served following the treatment of different doses of the
compounds for 72 h. As shown in Table 1, cell viability
was reduced following the treatments. Using these data,
the IC50 values were obtained and summarized in
Table 2. Cell viability of HepG2, T47D and HCT116 cells
were reduced upon treatment with 3-BC, 3-TFC and 4,




Fig. 2 Fluorescence microscopy of the HepG2, T47D and HCT116 cells treated with the 3-BC, 3-NC, 3-TFC and 4, 5-MC (at IC50 values). Fluorescence
images of the cells stained with Hoechst 33258 after 72 h. All of the four investigated chromenes induced condensation and fragmentation of the nuclei
(arrows). Magnification, 200 ×
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values of 60 ± 3.0, 80 ± 4.0 and 140 ± 3.0 nM in HepG2
cells, 65 ± 2.0, 75 ± 4.0 and 160 ± 5.0 nM in T47D cells
and 50 ± 3.0, 75 ± 2.0 and 120 ± 4.0 nM in HCT116 cells,
respectively (Table 2). Cell viability assays in HepG2,
T47D and HCT116 cells treated with 3-NC were pre-
viously described [21] (Table 2). This compound was
found to be highly active with IC50 values of 55 ± 2.0,
60 ± 3.0 and 50 ± 2.0 nM in HepG2, T47D and
HCT116 cells, respectively [21]. As shown in Tables 1
and 2, the 3-NC was more active to the cells in com-
parison with other compounds. Furthermore, all cells
were slightly less sensitive to compound 4, 5-MC.
Among these compounds, 3-NC was selected for next
studies.Morphological assay of the apoptotic cells
To induce apoptosis, cells were cultured at a density of
1 × 105 cells/ml in the presence of indicated concentra-
tions (IC50 Values) of the 3-BC, 3-NC, 3-TFC and 4, 5-
MC for 72 h. We stained harvested cells with Hoechst
33258 to detect the apoptotic cells (Fig. 2). Under fluor-
escence microscope, the staining showed that the nu-
cleus was large and round, without condensation and
fragmentation in the control cells. However, cells treated
with the compounds exhibited chromatin condensation
and fragmentation, a typical morphological feature of
apoptosis. These data indicate that the investigated com-
pounds causes apoptosis in the three cell lines. Given
high anti-proliferative activity of 3-NC compared to
other chromene compounds (see Tables 1 and 2), the 3-
NC was chosen for further studies.Apoptosis assay by flow cytometry
We used flow cytometric method to confirm apoptosis.
The detection of surface exposed phosphatidyl-serine
(PS) by AnnexinV-FITC has been shown to be a general
and early marker of apoptosis as a result of redistribu-
tion of the plasma membrane of cells following the oc-
currence of apoptosis [26]. Consistent with previous
data on morphological changing of cells, apoptosis was
mostly observed after 72 h of exposure to the 3-NC (at
IC50 values). Early apoptosis (lower right quadrant) and
late apoptosis/necrosis (upper right quadrant) were
clearly evident in dot plots of Fig. 3. Flow cytometric
analysis using Annexin V/PI staining showed that treat-
ment of the cells with the 3-NC causes more than 60 %
of HepG2 and T47D and more than 70 % of HCT116
cells to die through apoptosis.Evaluation of Bcl2 and Bax proteins expression upon
3-NC treatment
Recently, we reported the activation of caspase-9,
caspase-3 and down regulation of IAP family members
in HepG2, T47D and HCT 116 cells treated with the 3-
NC [21]. Given that apoptosis inducing agents fre-
quently signal through changes in the expression of Bcl2
family proteins, we now decided to examine possible al-
terations of Bcl2 and Bax proteins. Thus expression of
Bcl2 (anti-apoptotic) and Bax (pro-apoptotic) before and
after treatment with 3-NC at IC50 values was examined
in these cell lines using western blot (Fig. 4a and b).
Although Bcl2 expression in HepG2 cells was reduced
dramatically after 24 h, its reduction in T47D was resist-
ant to drug such that the major reduction occurred
AnnexinV-FITC
PI
Fig. 3 Flow cytometry apoptosis detection of the HepG2, T47D and HCT116 cells treated with the 3-NC. The cells were treated with indicated
concentrations (IC50 values) of the 3-NC and harvested after 48 and 72 h for double staining (Annexin V/PI) flow cytometric assay. As is evident from
Figure, after 72 h, a shift occurred from early apoptosis (lower-right quadrant) to late apoptosis or necrosis (upper-right quadrant). The results are
those of two independent experiments
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Bcl2 almost completely disappeared in all of the three
cell lines. Simultaneous with down regulation of Bcl-2,expression of Bax was increased in all three cell lines
upon treatment with 3-NC (Fig. 4). Bax expression in
T47D and HCT116 cells increased by almost 50 %, while
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Fig. 4 Expression level of Bcl2 and Bax proteins in the HepG2, T47D and HCT116 cells. a Following the treatment of the cells with indicated
concentrations (IC50 values) and times (24-48 h) of the 3-NC, the cells were harvested and subjected to Western Blot analysis using polyclonal
antibodies against Bcl2 and Bax. β-Actin was used as the loading control. b The protein levels of Bcl2 and Bax in control and treated cells were
quantified by ImageJ software and normalized to β-actin band intensity. The relative intensities of the proteins over that of Actin for the control
cells were set as 100 %. Each data was repeated three times (n = 3)
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ing that HepG2 is the most sensitive cell to chromene
treatment.
Discussion
The induction of apoptosis is suggested to be an efficient
strategy for treatment of cancer [27], because, cell num-
bers are dependent upon the extent of cell proliferation
and death. However, cancer cells have developed various
mechanisms to resist apoptotic cell death [27]. One of
these mechanisms is over-expression of anti-apoptotic
Bcl2 family proteins, which give rise to apoptosis resist-
ance decreasing efficiency of therapeutics [28, 29]. The
Bcl2 family of proteins is the central regulators of the
mitochondrial cell-intrinsic apoptotic [30, 31]. The Bcl2
itself binds to pro apoptotic members such as Bax, pre-
venting pore formation and cytochrome c release [31].
In contrast, increase in expression of Bax, induces cell
death eliminating tumor cells [32, 33]. Given numerous
reports underlining reduced expression of Bax and in-
creased expression of Bcl2 in many drug-resistant tumor
cells and recent reports showing the ability of 4-aryl-4H-
chromenes family to induce procaspase-9 cleavage and
thus activation we hypothesized that induction of mito-
chondrial apoptosis pathway by chromene compounds
might be mediated through the Bcl2 and Bax proteins.HepG2, T47D and HCT116 Cells were treated with
various concentrations (IC50 values) of 3-NC, which
caused strong induction of apoptosis in a time and dose
dependent manner. These observations agree with the
previous reports [21]. Interestingly, Bax and Bcl2
responded differently to the drug in a cell type
dependent manner. For instance, levels of Bcl2 expres-
sion in HepG2 and HCT116 cells strongly decreased
time-dependently after 24 and 48 h. In T47D cells high
levels of Bcl2 were still seen after 24 h. However, pro-
longed exposure (48 h) to the drug, resulting in de-
creased Bcl2 expression levels (Fig. 3). The expression of
Bax also changed in all of these cell lines after treatment
with the drug in a time-dependent manner. In HepG2
and HCT116 cells, Bax level considerably increased
following 48 h of treatment while in T47D cells, slightly
increased after 24 and 48 h of treatment. The pattern of
changes in the expression of Bax and Bcl2 is evidence
for greater resistance to the drug in T47D cells and
higher sensitivity in HCT116 cells (Figs. 2 and 3 and
Table 1). Mechanism(s) by which 4-aryl-4H-chromenes
modulate the Bcl2 and Bax protein levels remains un-
known. Microtubule inhibitors as apoptosis-inducing
agents [34]; observed mechanisms are phosphorylation
of Bcl2 leading to protein degradation and induction
of apoptosis [35]. These compounds (as microtubule
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proteins or more likely activate degradation pathways
of this protein [20]. However, it has been recently re-
ported that ethyl 2-amino-6-bromo-4-(1-cyano-2-eth-
oxy-2-oxoethyl)- 4H-chromene-3-carboxylate (HA14-
1) binds to Bcl2 protein, and blocks its anti-apoptotic
function in HL-60 cells [15, 36]. Apoptotic effects of
HA14-1 depend on Apaf-1 and activation of caspase-
9, followed by caspase-3 [15]. It has been suggested
that a high ratio of Bax to Bcl2 can lead to collapse of
mitochondrial membrane potential, resulting in re-
lease of cytochrome c and consequently causes cell
apoptosis [37, 38]. Our data also confirm that de-
creased Bcl2 protein expression, its inhibitory effect
on Bax and caspase-9 was removed and leads to over
expression of Bax and finally activation of caspase-9.
Although, activation of caspase-9 also leads to loss of
mitochondrial membrane potential by cleaving anti-
apoptotic members of Bcl2 family including Bcl-xL
and Bcl2 [39]. Therefore, altered ratio of pro-
apoptotic and anti-apoptotic Bcl2 family members
might be an important key question to understand the
sensitizing effect of 3-NC in these cells. It has been
greatly reported that Bcl2 is inactivated by phosphor-
ylation when cells are arrested in G2/M [40, 41].
Furthermore, inhibition of tubulin polymerization and
cell cycle arrest at G2/M phase has been reported
for 4-aryl-4H-chromenes family [16–18]. Our data
showed that the expression of Bcl2 proteins decreased
after 24 and 48 h of 3-NC treatment. In contrast, con-
siderable change was noted in the expression of Bax
protein. Thus, it seems that the Bcl2 family of proteins
might act as downstream signal in the process of 3-
NC-induced apoptosis in these human cancer cells.
In previous studies, we have reported down-regulation
of several IAPs such as XIAP, cIAP2 and survivin in
HepG2, T47D and HCT116 human cancer cells [21].
The expression changes of apoptotic regulators such as
Bcl2 and IAPs is an attractive strategy for exploring their
role in raising the possibility of tumor cell apoptosis and
thus defining potential therapeutic strategies. IAP pro-
teins have been identified to inhibit apoptosis via their
function as direct or indirect inhibitors of initiator as
well as executioner caspases, regulating cell cycle pro-
gression and modulating receptor-mediated signal trans-
duction [42, 43]. Our findings indicated that a cell death
associated with the down-regulation of IAP proteins
provides a powerful model for investigating mitochon-
drial control of cell death in these human cancer cells.
These findings are compatible with the reports that
over-expression of IAP family proteins inhibits apoptosis
induced by Bax and other pro-apoptotic Bcl2 family pro-
teins, which are known for their ability to target mitochon-
dria and induce cytochrome c release [44]. Although, IAPproteins, do not interfere directly with Bax-mediated re-
lease of cytochrome c [45], some of the findings indicating
that the human IAPs such as XIAP, c-IAP1, c-IAP2, and
survivin block caspase activation and apoptosis down-
stream of Bax, Bak and cytochrome c [44, 45].
Then, these compound from 4-aryl-4H-chromenes
family can be very effective in overcoming chemoresis-
tance because they upregulate Bax and down regulate
Bcl2 leading to cytochrome c release from one hand and
antagonizing IAPs unleashing caspase-9 and 3 activities
on the other hand. Combination of these effects on cell
lines derived from various tissues may render chromenes
as effective cancer therapy agents.
In conclusion, we have reported four compounds from
4-aryl-4H-chromenes family with high apoptotic activity.
Induction of apoptosis by an active compound (3-NC)
was achieved by down-regulation of Bcl2 and up-
regulation of Bax. Our observations show that for an ef-
fective elimination of cancerous cells simultaneous
down-regulation of Bcl2 following by over expression of
Bax is a preferred approach and persistent expression of
Bcl2 and IAP proteins can be a mechanism by which





chromene; 4: 5-MC, 2-amino-4-(4,5-methylenedioxyphenyl)-3-cyano-7-
(dimethylamino)-4H-chromene; Apaf-1: Apoptotic factor-1; Bcl2: B-cell
lymphoma 2; BH: Bcl homology; BIR: Baculoviral IAP repeat; Caspases: Cysteine-
aspartic proteases; FBS: Fetal bovine serum; MTT: 3-(4, 5-dimethylthiazol-2-yl) 2,
5-diphenyl tetrazolium bromide; PBS: Phosphate-buffered saline; PS: Phosphatidyl-
serine; IAPs: Inhibitor of apoptosis proteins; XIAP: X-Linked Inhibitor of Apoptosis
Protein; cIAP: cellular inhibitor of apoptosis protein.
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